SAVA
Cassava Sciences Inc
$
2.250
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.290
Open
2.170
VWAP
2.22
Vol
773.68K
Mkt Cap
108.69M
Low
2.150
Amount
1.72M
EV/EBITDA(TTM)
--
Total Shares
47.98M
EV
-12.02M
EV/OCF(TTM)
--
P/S(TTM)
--
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q2
FY2024Q3
FY2024Q4
--
--
-0.400
-36.51%
--
--
-0.880
+44.26%
--
--
-0.680
+36%
Estimates Revision
The market is revising No Change the revenue expectations for Cassava Sciences, Inc. (SAVA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 22.95%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+22.95%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Cassava Sciences Inc (SAVA.O) is 0.00, compared to its 5-year average forward P/E of -6.00. For a more detailed relative valuation and DCF analysis to assess Cassava Sciences Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-6.00
Current PE
0.00
Overvalued PE
39.61
Undervalued PE
-51.60
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
24.00
Undervalued EV/EBITDA
-28.64
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.90
Current PS
0.00
Overvalued PS
60.66
Undervalued PS
-22.87
Financials
Annual
Quarterly
FY2025Q1
YoY :
+23.34%
-24.59M
Operating Profit
FY2025Q1
YoY :
-193.45%
-23.40M
Net Income after Tax
FY2025Q1
YoY :
+11.63%
-0.48
EPS - Diluted
FY2025Q1
YoY :
-40.73%
-11.34M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
253.9K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 3083.17% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
450.1K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
253.9K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
SAVA News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
07:40:58
Cassava Sciences appoints Hulihan as Chief Medical Officer
2025-08-04 (ET)
2025-08-04
07:36:27
Cassava reports preclinical study on simufilam for TSC-related epilepsy
2025-06-30 (ET)
2025-06-30
07:07:42
Cassava Sciences presents poster at TSC 2025 on Simufilam
Sign Up For More Events
Sign Up For More Events
News
5.0
08-07NewsfilterCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
9.0
08-04NewsfilterCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
4.5
05-28SeekingAlphaEditas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit
Sign Up For More News
People Also Watch
HURC
Hurco Companies Inc
18.155
USD
-3.33%
MCRB
Seres Therapeutics Inc
14.530
USD
+2.25%
EUDA
EUDA Health Holdings Ltd
2.520
USD
-3.45%
SLDB
Solid Biosciences Inc
6.080
USD
-3.34%
QIPT
Quipt Home Medical Corp
2.120
USD
-0.47%
GNSS
Genasys Inc
1.630
USD
+1.24%
MNSB
MainStreet Bancshares Inc
20.420
USD
+0.89%
ULBI
Ultralife Corp
6.800
USD
+3.19%
LCTX
Lineage Cell Therapeutics Inc
1.010
USD
+2.64%
CLYM
Climb Bio Inc
1.650
USD
-2.94%
FAQ
What is Cassava Sciences Inc (SAVA) stock price today?
The current price of SAVA is 2.25 USD — it has increased 3.21 % in the last trading day.
What is Cassava Sciences Inc (SAVA)'s business?
What is the price predicton of SAVA Stock?
What is Cassava Sciences Inc (SAVA)'s revenue for the last quarter?
What is Cassava Sciences Inc (SAVA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Cassava Sciences Inc (SAVA)'s fundamentals?
How many employees does Cassava Sciences Inc (SAVA). have?